Boston Therapeutics Announces Clinical Study Final Results Indicate That SUGARDOWN(R) Reduced the Post-Meal Elevation of Blood Glucose by up to 61% in Healthy Volunteers
January 28, 2013 07:30 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Jan 28, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...
Boston Therapeutics Approved in France to Initiate a Clinical Trial With SUGARDOWN(R) in Patients With Type II Diabetes
December 19, 2012 07:30 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwire - Dec 19, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of complex carbohydrate therapeutics to...
Boston Therapeutics to Present Corporate Update at the SeeThruEquity Smallcap & Microcap Investor Summit
November 29, 2012 07:00 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwire - Nov 29, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of complex carbohydrate therapeutics to treat...
Boston Therapeutics Reports Third Quarter and Nine Months 2012 Financial Results
November 14, 2012 15:39 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwire - Nov 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE)
SUGARDOWN® sales increased approximately 700% in the first nine months...
Boston Therapeutics' Newly Appointed Chief Operating Officer Invests $625,000 in the Company's S-1 Financial Offering
November 14, 2012 08:15 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwire - Nov 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
Boston Therapeutics Names Jonathan B.Rome Chief Operating Officer
November 13, 2012 08:15 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwire - Nov 13, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
Boston Therapeutics Wins FDA Approval to File an Abbreviated New Drug Application for PAZAMET(TM) to Treat Diabetes
October 04, 2012 07:01 ET
|
Boston Therapeutics
MANCHESTER, NH--(Marketwire - Oct 4, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and...
Boston Therapeutics Announces Filing of S-1 Registration Statement
September 24, 2012 11:51 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Sep 24, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
Boston Therapeutics Reports Second Quarter and Six Months 2012 Financial Results
August 14, 2012 13:48 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Aug 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) (OTCBB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate...
Boston Therapeutics to Present Corporate Update at the SeeThruEquity Microcap Investor Forum
July 16, 2012 07:00 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Jul 16, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE)(OTCBB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to...